A variety of novel thiazolidine derivatives (2-thioxothiazolidin-4-one and thiazolidine-2, 4-dione derivatives) have been prepared by using 2,4-diphenyl-2H-chromene-3-carbaldehyde and its derivatives as starting materials. This is the first example of the preparation of thiazolidine derivatives through this novel method. Structure evolution of the resulting thiazolidine derivatives leads to anticancer agents. Our preliminary data for some model compounds on three cancer cell lines (MCF7, A549 and B-16) suggested reasonable anticancer activity against the A549 and B-16 cell lines, with IC50 values of 20.7 and 20.4 μM, respectively. This method is operationally simple and works with a diverse range of substrates.
RobertsonM.J., HadzicG., AmbrusJ., PomeD.Y., HydeE., WhitingA., MarianaA., KleistL.V., ChauN., HauckeV., RobinsonP.J., McCluskeyA. (2012) The rhodadyns, a new class of small molecule inhibitors of dynamin GTPase activity. Medicinal Chemistry Letters, 3, 352–356.
2.
VermaA., SarafS.K. (2008) 4-Thiazolidinone-A biologically active scaffold. European Journal of Medicinal Chemistry, 43, 897–905.
3.
PrabhakarY.S., SolomonV.R., GuptaM.K., KattiS.B. (2006) QSAR and SPECTRAL-SAR in computational ecotoxicology. Heterocyclic Chemistry, 4, 161–249.
4.
(a) HavrylyukD., ZimenkovskyB., VasylenkoO., ZaprutkoL., LesykR. (2009) Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. European Journal of Medicinal Chemistry, 44, 1396–1404; (b) Joy JM, Jacob N, Kutty GN. (2005) Evaluation of hypoglycaemic effects of 4-thiazolidinones. Indian Drugs, 42, 47–51; (c) Zhou H, Wu S, Zhai S, Liu A, Sun Y, Li R, Zhang Y, Ekins S, Swaan PW, Fang B. (2008) Design, synthesis, cytoselective toxicity, structure–activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. Journal of Medicinal Chemistry, 51, 1242–1251.
